Hologic, Inc. (Nasdaq: HOLX) has announced that Charles J. Dockendorff has been elected to the Company's Board of Directors, effective immediately. Mr. Dockendorff also was appointed to the Company's Audit and Finance Committee.
Mr. Dockendorff, who has more than 25 years of experience in the global healthcare industry, was formerly the Executive Vice President and Chief Financial Officer of Covidien, a public medical device and supplies company acquired by Medtronic in 2015. At Covidien, Mr. Dockendorff was responsible for global financial management activities, including corporate accounting, tax, treasury, financial planning and investor relations, as well as internal audit and information services. Mr. Dockendorff joined Kendall Healthcare Products Company, the foundation of Covidien formerly known as Tyco Healthcare, in 1989 as controller. He was appointed CFO of Covidien in 1995 and held that position throughout the company's growth from $600 million in revenue to a diverse, $10 billion healthcare products leader.
"We're thrilled to welcome Chuck to Hologic's Board of Directors," said Steve MacMillan, the Company's Chairman, President and Chief Executive Officer. "As a proven business leader who brings a strong track record of value creation, Chuck's financial acumen and depth of experience in operations and strategy are a welcome addition to our Board."
Mr. Dockendorff is also a Director of Boston Scientific, Haemonetics, and Keysight Technologies. He is a Certified Public Accountant and holds a Bachelor's degree in Business Administration and Accounting from the University of Massachusetts, as well as a Master of Science degree in Finance from Bentley College.
Source & Image Credit: Hologic